Patients and Caregivers

About ROMA™

Know the right treatment path.

ROMA™ accurately stratified 94% of all epithelial ovarian tumors as high likelihood and 75% of all benign disease as low likelihood.

The Risk of Ovarian Malignancy Algorithm (ROMA™) is a qualitative serum test that combines the results of HE4 EIA, ARCHITECT CA 125 II™ and menopausal status into a numerical score.

ROMA is intended to aid in assessing whether a premenopausal or postmenopausal woman who presents with an ovarian adnexal mass is at high or low likelihood of finding malignancy on surgery. ROMA is indicated for women who meet the following criteria: over age 18, ovarian adnexal mass present for which surgery is planned, and not yet referred to an oncologist. ROMA must be interpreted in conjunction with an independent clinical and radiological assessment. The test is not intended as a screening or stand-along diagnostic assay.

This is an important and exciting new development in ovarian cancer research because it can help direct patients down the right treatment path for optimal care. Physicians can utilize this test, in combination with other information (physical, pelvic, and/or transvaginal exams) to identify patients with a high likelihood for malignancy who may have a better outcome when treated by a gynecologic oncologist.

Click here for the full ROMA package insert.